Corvus Pharmaceuticals CRVS Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $11.18M+12.4% | $9.94M+17.6% | $8.45M+7.4% | $7.87M+5.6% | $7.45M+24.8% | ||
| $3.7M+62.5% | $2.28M+7.6% | $2.12M-11.3% | $2.39M-3.3% | $2.47M+15.9% | ||
| $14.88M+21.8% | $12.22M+15.6% | $10.57M+3.0% | $10.26M+3.4% | $9.92M+22.4% | ||
| -$14.88M-21.8% | -$12.22M-15.6% | -$10.57M-3.0% | -$10.26M-3.4% | -$9.92M-22.4% | ||
| -$13.09M-12.7% | -$11.61M-18.1% | -$9.83M-29.2% | -$7.61M-148% | $15.73M+258% | ||
| -$13.69M-11.1% | -$12.32M-21.3% | -$10.16M-27.0% | -$8M-153% | $15.19M+225% | ||
| -$0.150.0% | -$0.15-25.0% | -$0.12-20.0% | -$0.10+23.1% | -$0.13+18.8% | ||
| -$14.85M-21.8% | -$12.19M-15.6% | -$10.54M-3.1% | -$10.23M-3.3% | -$9.9M-22.4% | ||
| -$14.88M-21.8% | -$12.22M-15.6% | -$10.57M-3.0% | -$10.26M-3.4% | -$9.92M-22.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Corvus Pharmaceuticals profitable?
- Corvus Pharmaceuticals is not currently profitable: it reported a net loss of $44.2M over the trailing twelve months.
- What is Corvus Pharmaceuticals's earnings per share?
- Corvus Pharmaceuticals's diluted EPS over the trailing twelve months is $-0.52.
- Where does Corvus Pharmaceuticals's income statement data come from?
- Every line is extracted from Corvus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.